Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Gandara on TS Expression in ALK-Positive NSCLC

June 19th 2012

Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer

Dr. Kris Discusses ASCO 2012 Lung Cancer Information

June 18th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.

Time Management: Balancing Clinical Education With Scientific Research

June 15th 2012

With careful attention to detail and conscientious efforts, clinical skills are likely to be transferable from clinical education to meeting research goals.

On the Horizon: Novel Inhibitors for Hematologic Malignancies

June 13th 2012

Increased understanding of the molecular mechanisms underlying the pathogenesis of hematologic cancers has led to the development of several promising new classes of targeted therapies.

JAK Pathway Yielding Results

June 13th 2012

JAK plays an important role in the formation and development of blood cells, and defects in the gene have been identified in myeloproliferative neoplasms.

Dr. Adjei on the Need for Targeted Therapy Education

June 12th 2012

Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education

IPCC Case-Based Discussion: How Should We Sequence Therapy?

June 12th 2012

Three case studies focused on how best to sequence therapy in prostate cancer were presented by Daniel P. Petrylak, MD, and discussed by a panel that included Robert Dreicer, MD, and Oliver Sartor, MD.

Grappling With the Genome: Cancer Centers Approach Puzzle in Different Ways

June 11th 2012

As the cost of sequencing and analyzing genetic data continues to fall, the nation's leading cancer centers keep unveiling ambitious new clinical programs and research projects that will change the way every cancer specialist practices.

University of Michigan Comprehensive Cancer Center: Leading the Way in Targeted Therapies Cancer Care

June 7th 2012

The U-M Comprehensive Cancer Center in Ann Arbor offers diagnostic, treatment, and support services while serving as a model for other branches of the U-M Health System and for academic peer organizations nationwide.

Dr. Wood on Family Histories and Genetic Counseling

June 5th 2012

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Dr. Robert on the Trametinib METRIC Trial Results

June 4th 2012

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

CDX-011 Shows Promise in GPNMB-Positive Triple-Negative Breast Cancer

May 23rd 2012

CDX-011, a targeted therapy designed to treat patients with advanced breast cancer, appears to increase PFS in TNBC patients who have received multiple prior lines of therapy and express GPNMB.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

May 16th 2012

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Dr. Chapman on BRAF/MEK Combination for Melanoma

May 16th 2012

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Goy on Crizotinib for Pediatric Patients With ALCL

May 16th 2012

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Crizotinib Active in ALK-Positive Pediatric Cancers

May 16th 2012

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Spector Discusses Breast Cancer Heterogeneity

May 14th 2012

Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity

Dr. Ellis on Heterogeneity Impacting Biomarker Efficacy

May 9th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

Moffitt Cancer Center: Cutting-Edge, Total Cancer Care

May 9th 2012

Located in Tampa, Florida, Moffitt Cancer Center enjoys a reputation as one of the world's most sophisticated cancer centers.

Identifying Appropriate Patients for HER2-Targeted Therapies

May 6th 2012

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.